Redeye: IDL Biotech - Opportunity at a discount

We provide a short research update with the latest financial estimates and valuation following IDL Biotech’s Q1’19 report.

Read more and download the research update: 

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Om oss

IDL Biotech AB (publ) är ett svenskt diagnostikföretag som utvecklar, producerar och marknadsför in vitro diagnostiska tester inom områdena onkologi och bakterologi.